{"product_id":"seeing-the-problem-before-it-happens-how-carotid-ultrasound-helps-predict-heart-attacks-and-strokes","title":"Seeing the Problem Before It Happens: How Carotid Ultrasound Helps Predict Heart Attacks and Strokes","description":"\u003cp\u003eCarotid ultrasound is a safe, painless imaging test that measures the buildup of fatty plaque in the neck arteries, giving doctors a direct window into your risk for future heart attacks and strokes. This review of decades of research, conducted by Swiss and German specialists, shows that measuring carotid plaque—rather than relying only on traditional risk factors like cholesterol and blood pressure—can more accurately identify people who will experience cardiovascular events. The research demonstrates that carotid plaque measurement performs just as well as coronary calcium scoring (a widely used heart imaging test) and can help reclassify patients who are mistakenly labeled \"low risk\" by standard risk calculators.\u003c\/p\u003e\n\n\u003ch1\u003eSeeing the Problem Before It Happens: How Carotid Ultrasound Helps Predict Heart Attacks and Strokes\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eWhy This Research Matters: The Limits of Traditional Risk Assessment\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#how-it-works\"\u003eHow Carotid Ultrasound Works: A Closer Look at the Technology\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#outcomes\"\u003eWhat the Research Shows: Carotid Ultrasound and Health Outcomes\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#comparison\"\u003eCarotid Plaque vs. Coronary Calcium: Head-to-Head Comparisons\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#treatment\"\u003eCan Medical Treatment Reverse or Slow Carotid Atherosclerosis?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#what-to-measure\"\u003eWhat Should Be Measured: IMT, Plaque, or Calcium?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eClinical Implications: What This Means for You\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What the Research Cannot Tell Us\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eCarotid plaque presence is a stronger predictor of heart attacks and strokes than IMT alone, according to multiple large studies.\u003c\/li\u003e\n\u003cli\u003eCarotid ultrasound performs as well as coronary calcium scoring for predicting cardiovascular events, but without any radiation exposure.\u003c\/li\u003e\n\u003cli\u003eIn the MESA study, only carotid plaque presence—not coronary calcium or IMT—predicted stroke or transient ischemic attack after 9.5 years.\u003c\/li\u003e\n\u003cli\u003eA meta-analysis of 41 randomized trials found that active treatment reduces cardiovascular events even when IMT does not visibly change.\u003c\/li\u003e\n\u003cli\u003eEuropean ESC guidelines now say carotid artery scanning should be considered for adjusting risk level, especially in intermediate-risk patients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eWhy This Research Matters: The Limits of Traditional Risk Assessment\u003c\/h2\u003e\n\n\u003cp\u003eWhenever illness or injury strikes, a fundamental question arises: could it have been prevented? Identifying factors that predict future risk—so that risk can be managed and reduced—has been the focus of extensive ongoing research worldwide.\u003c\/p\u003e\n\n\u003cp\u003eThe landmark INTERHEART study showed that major independent cardiovascular risk factors contribute to \u003cstrong\u003e90% of cardiovascular events\u003c\/strong\u003e (heart attacks, strokes, and related conditions). According to the Swiss Federal Statistical Office, cardiovascular and cancer diseases remained the leading causes of mortality in Switzerland in 2015. The National Health Accounts showed that healthcare spending was highest for cardiovascular disease at \u003cstrong\u003e15.6%\u003c\/strong\u003e, and together with cancer, these conditions accounted for \u003cstrong\u003e22% of healthcare expenditure\u003c\/strong\u003e in Switzerland.\u003c\/p\u003e\n\n\u003cp\u003ePrevention of atherosclerosis-related diseases is therefore a primary healthcare priority. Traditionally, primary care physicians assess atherosclerosis risk by checking patients for traditional risk factors. The modification of just seven risk factors—\u003cstrong\u003esmoking, high blood pressure, high cholesterol, obesity, sedentary lifestyle, poor nutrition, and diabetes mellitus\u003c\/strong\u003e—has great potential to prevent premature illness and death in the population.\u003c\/p\u003e\n\n\u003cp\u003eHowever, there is a critical problem: \u003cstrong\u003emany patients who arrive at the hospital with a first ischemic event (heart attack or stroke) were previously classified as \"low risk\"\u003c\/strong\u003e by standard risk calculators such as PROCAM and SCORE. This means the calculators are missing people who are actually in danger.\u003c\/p\u003e\n\n\u003cp\u003eThe authors of this review previously studied populations in Olten (Switzerland) and Koblenz (Germany) and found that the sensitivity of global risk calculators like PROCAM and SCORE is low for detecting advanced carotid atherosclerosis when measured as total carotid plaque area. They also found that the agreement between PROCAM and SCORE regarding risk categories is limited. This means two different risk calculators can label the same patient differently—a confusing and potentially dangerous situation. Direct visualisation of atherosclerosis (the actual buildup of plaque in the arteries) may therefore be warranted to reclassify individuals according to their true personal risk.\u003c\/p\u003e\n\n\u003ch2 id=\"how-it-works\"\u003eHow Carotid Ultrasound Works: A Closer Look at the Technology\u003c\/h2\u003e\n\n\u003cp\u003eCarotid ultrasound is performed with a linear array probe—a handheld device placed on the neck—using a high frequency of \u003cstrong\u003eat least 7 MHz\u003c\/strong\u003e to obtain sufficient resolution to image small structures. The image resolution depends on the depth and frequency used and is typically around \u003cstrong\u003e0.3 mm\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe anatomical region of interest is the \u003cstrong\u003etunica intima\u003c\/strong\u003e (the innermost layer of the artery wall), which is assessed with 2D imaging without Doppler. \u003cstrong\u003eIntima-media thickness (IMT)\u003c\/strong\u003e is the distance between the endothelium (the thin cell layer lining the artery) and the tunica adventitia (the outer layer of the vessel wall). According to the Mannheim consensus (an international agreement on measurement standards), IMT is preferably measured in the far wall segment of the last 10 mm of the common carotid artery.\u003c\/p\u003e\n\n\u003cp\u003eOne major challenge with carotid IMT measurements lies in the diversity of methods used across different studies. The variability of measurements is lowest in the far wall of the common carotid artery when plaque is excluded—but this gain in reproducibility comes at a cost: a \u003cstrong\u003eloss in predictive power for cardiovascular events\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eTotal plaque area (TPA)\u003c\/strong\u003e is the sum of the longitudinal area of all plaques in the carotid wall. It is measured from the clavicles to the jaws using multiple angles to capture the full extent of plaque in the carotid tree, including the proximal brachial artery if possible. More recently, \u003cstrong\u003etotal plaque volume (TPV)\u003c\/strong\u003e has become available using the Philips iU 22 ultrasound system equipped with a single-sweep volumetric transducer, which covers 3.8 cm of the carotid artery and visualises the distal part of the common carotid artery, the bulb, and the proximal parts of the internal carotid artery. Offline software calculates the plaque areas from all obtained transversal images to determine the total plaque volume.\u003c\/p\u003e\n\n\u003cstrong\u003eThe key advantages of TPA measurements include:\u003c\/strong\u003e\n\u003cul\u003e\n  \u003cli\u003eHigh reproducibility (consistent results when repeated)\u003c\/li\u003e\n  \u003cli\u003eVendor independence (no additional costs for surface tracing software)\u003c\/li\u003e\n  \u003cli\u003eResults can be obtained without additional software\u003c\/li\u003e\n  \u003cli\u003eCaptures more plaque than TPV, which may miss plaques located outside its 3.8 cm field of view\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eHowever, TPV can detect plaques located laterally in the vessel that may not be visible with the TPA method, so combining both approaches provides the most complete picture. The correlation between TPA and TPV is very strong, with a correlation coefficient of r² = 0.921 (p \u0026lt;0.0001).\u003c\/p\u003e\n\n\u003cp\u003eFor clinical purposes, plaque is most commonly defined as an \u003cstrong\u003eIMT increase of more than 1.5 mm\u003c\/strong\u003e or a \u003cstrong\u003efocal thickening of more than 50% compared with adjacent structures\u003c\/strong\u003e. However, the definition of atherosclerotic plaque versus non-atherosclerotic intimal thickening has not been used uniformly in the medical literature. Researchers have used a wide variety of measurement approaches:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eIMT increase \u0026gt;1.0 mm (Spence 1991)\u003c\/li\u003e\n  \u003cli\u003eDoubling of IMT (Spence 1991; Mannheim Consensus)\u003c\/li\u003e\n  \u003cli\u003eIMT thickening \u0026gt;1.2 mm (Handa)\u003c\/li\u003e\n  \u003cli\u003eSubjective assessment (Polak)\u003c\/li\u003e\n  \u003cli\u003eEncroachment into the lumen by 0.5 mm (Mannheim Consensus)\u003c\/li\u003e\n  \u003cli\u003eIMT increase ≥1.5 mm (Mannheim Consensus; Spence)\u003c\/li\u003e\n  \u003cli\u003eTexture changes (Singh)\u003c\/li\u003e\n  \u003cli\u003ePlaque present or absent (Nambi)\u003c\/li\u003e\n  \u003cli\u003eNumber of plaques (Plichart)\u003c\/li\u003e\n  \u003cli\u003ePlaque thickness in mm (Rundek)\u003c\/li\u003e\n  \u003cli\u003ePlaque area in mm² (Spence)\u003c\/li\u003e\n  \u003cli\u003ePlaque volume in mm³ (Baber)\u003c\/li\u003e\n  \u003cli\u003eEcho lucency using gray scale (Stein)\u003c\/li\u003e\n  \u003cli\u003ePlaque vascularity using contrast agents (Coli)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis lack of standardization has made it difficult to compare results across studies and apply them consistently in clinical practice.\u003c\/p\u003e\n\n\u003ch2 id=\"outcomes\"\u003eWhat the Research Shows: Carotid Ultrasound and Health Outcomes\u003c\/h2\u003e\n\n\u003cp\u003eOutcome studies examining the relationship between the amount of carotid atherosclerosis and the incidence of heart and brain ischemic events are numerous. The largest ones include at least 4,000 subjects in cohort studies. Below are the key findings from these major studies.\u003c\/p\u003e\n\n\u003cp\u003eOne of the first studies on the prognostic impact of atherosclerosis imaging using carotid ultrasound was published in \u003cstrong\u003e1991\u003c\/strong\u003e. In \u003cstrong\u003e1,288 Finnish men\u003c\/strong\u003e, coronary event risk increased compared with structural changes: \u003cstrong\u003e2.2-fold for intimal thickening\u003c\/strong\u003e (not statistically significant), \u003cstrong\u003e4.2-fold for small carotid plaques\u003c\/strong\u003e (p \u0026lt;0.01), and \u003cstrong\u003e6.7-fold for stenotic plaque\u003c\/strong\u003e (p \u0026lt;0.01). In other words, the more advanced the plaque, the dramatically higher the risk of a heart event.\u003c\/p\u003e\n\n\u003cp\u003eIn \u003cstrong\u003e1995\u003c\/strong\u003e, Japanese researchers found that carotid stenosis (narrowing) and plaque ulcerations were predictive for ischemic stroke. In \u003cstrong\u003e1996\u003c\/strong\u003e, Belcaro and colleagues found that increases in plaque burden in carotid and femoral arteries predicted cardiovascular events and death in \u003cstrong\u003e2,322 asymptomatic subjects\u003c\/strong\u003e after a follow-up of 6 years. This was later confirmed in the CAFES-CAVE study of \u003cstrong\u003e13,221 low-risk subjects\u003c\/strong\u003e after 10 years of follow-up.\u003c\/p\u003e\n\n\u003cp\u003eSpence showed in \u003cstrong\u003e2002\u003c\/strong\u003e that total plaque area (TPA) was predictive for cardiovascular events, with increasing risk in the higher quartiles (quarters) of TPA. The analysis included \u003cstrong\u003e1,686 patients\u003c\/strong\u003e, most of whom had experienced a previous stroke or transient ischemic attack (a \"mini-stroke\"). Of these, 684 were originally primary care patients. For these patients, adding posterior test probabilities based on Bayes' theorem (a mathematical approach to updating risk estimates) improved discrimination for predicting future heart attacks after 3.3 years of follow-up: the area under the curve (AUC, a measure of how well a test discriminates between those who will and won't have an event) improved from \u003cstrong\u003e0.68 for the standard NCEP III risk model to 0.75 for TPA-based posterior probability (p = 0.038)\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eIn \u003cstrong\u003e2003\u003c\/strong\u003e, Hollander reported on \u003cstrong\u003e6,913 prospectively followed healthy subjects\u003c\/strong\u003e in the Rotterdam study and found that carotid IMT (including regions with carotid plaque) was a \u003cstrong\u003estronger predictor of future stroke than carotid plaque alone\u003c\/strong\u003e. In \u003cstrong\u003e2004\u003c\/strong\u003e, Van der Meer reported on \u003cstrong\u003e6,389 subjects\u003c\/strong\u003e from the Rotterdam study and found that carotid structural changes (carotid and femoral plaque, carotid IMT including plaque, and aortic plaque) had \u003cstrong\u003eequal predictive power for subsequent heart attack\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eIn \u003cstrong\u003e2007\u003c\/strong\u003e, Stein and colleagues reported on \u003cstrong\u003e6,226 originally healthy subjects\u003c\/strong\u003e from the Norwegian Tromsø study. They found that TPA was a \u003cstrong\u003estronger, statistically significant marker for heart attack than IMT, especially in women\u003c\/strong\u003e, after correcting for several conventional cardiovascular risk factors. This observation remained significant after an extended follow-up of 15 years.\u003c\/p\u003e\n\n\u003cp\u003eIn a smaller study from China, Xie and colleagues screened \u003cstrong\u003e1,734 subjects\u003c\/strong\u003e for future heart attack and stroke and found that \u003cstrong\u003eall measures of structural changes in the carotid arteries\u003c\/strong\u003e (IMT measured at six sites, TPA, and number of plaques) were effective for risk prediction after adjusting for conventional cardiovascular risk factors.\u003c\/p\u003e\n\n\u003cp\u003eIn \u003cstrong\u003e2010\u003c\/strong\u003e, Lorenz reported on the atherosclerosis progression study including \u003cstrong\u003e4,904 low-risk patients\u003c\/strong\u003e with 10 years of follow-up. Carotid IMT derived from the common carotid artery, the bulb, and the internal carotid artery was \u003cstrong\u003eless predictive than the Framingham and SCORE risk models\u003c\/strong\u003e—but notably, only 5% of these subjects had carotid plaques, which may explain the weaker performance.\u003c\/p\u003e\n\n\u003cp\u003eAlso in \u003cstrong\u003e2010\u003c\/strong\u003e, Chambless published results from the Atherosclerosis Risk in Communities (ARIC) study, in which \u003cstrong\u003e13,145 subjects\u003c\/strong\u003e were followed for 15 years. The AUC increased \u003cstrong\u003esignificantly\u003c\/strong\u003e with the addition of carotid IMT or carotid plaque to traditional risk factors.\u003c\/p\u003e\n\n\u003cp\u003eIn \u003cstrong\u003e2011\u003c\/strong\u003e, Mathiesen and colleagues reported on \u003cstrong\u003e6,584 subjects\u003c\/strong\u003e in the Tromsø study and found that \u003cstrong\u003eTPA—but not common carotid IMT—was predictive for incident ischemic stroke\u003c\/strong\u003e after multivariate adjustment. In the same year, Polak reported that in \u003cstrong\u003e2,965 members of the Framingham Offspring Study\u003c\/strong\u003e followed for 7 years, both internal carotid IMT and internal carotid plaque formation (defined as IMT ≥1.5 mm) \u003cstrong\u003esignificantly improved the AUC\u003c\/strong\u003e compared with the Framingham risk equation alone.\u003c\/p\u003e\n\n\u003ch3\u003eMajor Outcome Studies Using Carotid IMT and Plaque\u003c\/h3\u003e\n\n\u003cp\u003eThe following are the key large-scale studies (each with at least 4,000 participants) that examined how well carotid artery measurements predict heart attacks and strokes. A hazard ratio (HR) above 1.0 means higher risk; the confidence interval (CI) shows the range of uncertainty around that estimate. If the CI does not include 1.0, the result is statistically significant.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCAFES-CAVE (10,000 subjects):\u003c\/strong\u003e Mortality with no plaque: 0.1% events. With carotid plaque: 3.0% events.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRotterdam study (6,389 subjects):\u003c\/strong\u003e Heart attack risk with plaque present vs. absent: HR 1.6 (95% CI 1.2–2.2).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRosvall (5,163 subjects):\u003c\/strong\u003e Heart attack risk with plaque: HR 1.8 (95% CI 1.5–2.9). IMT top vs. bottom third: HR 1.5 (95% CI 0.8–2.6).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRosvall (5,163 subjects):\u003c\/strong\u003e Stroke risk with plaque: HR 1.3 (95% CI 0.8–2.1). IMT top vs. bottom third: HR 2.5 (95% CI 1.2–5.4).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eARIC men (5,552 subjects):\u003c\/strong\u003e Heart attack risk with IMT ≥1.0 mm: HR 1.9 (95% CI 1.3–2.7).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eARIC women (7,685 subjects):\u003c\/strong\u003e Heart attack risk with IMT ≥1.0 mm: HR 5.1 (95% CI 3.1–8.4).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eARIC women (7,685 subjects):\u003c\/strong\u003e Stroke risk, IMT \u0026lt;0.6 vs. \u0026gt;1.0 mm: HR 8.5 (95% CI 3.5–20.7).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eARIC men (6,349 subjects):\u003c\/strong\u003e Stroke risk, IMT \u0026lt;0.6 vs. \u0026gt;1.0 mm: HR 3.6 (95% CI 1.5–9.2).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTromsø study (6,257 subjects):\u003c\/strong\u003e Heart attack risk, TPA top vs. bottom third: HR 2.5 (95% CI 2.1–3.0).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTromsø men (6,226 subjects):\u003c\/strong\u003e Heart attack risk, TPA top vs. bottom third: HR 1.6 (95% CI 1.04–2.4).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTromsø women (6,226 subjects):\u003c\/strong\u003e Heart attack risk, TPA top vs. bottom third: HR 4.0 (95% CI 2.2–7.2).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTromsø men (6,226 subjects):\u003c\/strong\u003e Heart attack risk, IMT top vs. bottom quarter: HR 1.7 (95% CI 0.98–3.1).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTromsø women (6,226 subjects):\u003c\/strong\u003e Heart attack risk, IMT top vs. bottom quarter: HR 2.9 (95% CI 1.1–7.7).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTromsø men (6,844 subjects):\u003c\/strong\u003e Stroke risk, TPA top vs. bottom third: HR 1.7 (95% CI 1.2–2.5).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTromsø women (6,844 subjects):\u003c\/strong\u003e Stroke risk, TPA top vs. bottom third: HR 1.6 (95% CI 1.04–2.5).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTromsø men (6,844 subjects):\u003c\/strong\u003e Stroke risk, IMT top vs. bottom quarter: HR 1.4 (95% CI 0.8–2.4).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTromsø women (6,844 subjects):\u003c\/strong\u003e Stroke risk, IMT top vs. bottom quarter: HR 1.3 (95% CI 0.7–2.3).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMESA (6,698 subjects):\u003c\/strong\u003e Cardiovascular disease risk, IMT top vs. bottom quarter: HR 1.7 (95% CI 1.2–2.5).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMESA (4,955 subjects):\u003c\/strong\u003e Cardiovascular disease risk with carotid score: HR 1.2 (95% CI 1.2–1.4).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCoronary Artery Calcium Studies (for Comparison)\u003c\/h3\u003e\n\n\u003cp\u003eTo understand how carotid ultrasound compares with the established coronary calcium test, it helps to know what the calcium data show. Coronary artery calcium (CAC) scoring uses CT scans to measure calcified plaque in the heart's arteries. Major studies found:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRaggi (10,377 subjects):\u003c\/strong\u003e Mortality prediction AUC 0.72–0.78, p = 0.001.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDetrano (6,772 subjects):\u003c\/strong\u003e Major adverse cardiovascular events AUC 0.79–0.83, p = 0.009.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eArad (4,903 subjects):\u003c\/strong\u003e Major adverse cardiovascular events AUC 0.68–0.79, p = 0.001.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eErbel (4,129 subjects):\u003c\/strong\u003e Major adverse cardiovascular events AUC 0.65–0.76, p = 0.001.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMESA (6,814 subjects):\u003c\/strong\u003e Major adverse cardiovascular events AUC 0.75–0.80, p = 0.001.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMESA (6,698 subjects):\u003c\/strong\u003e Cardiovascular disease risk, top vs. bottom quarter of calcium: HR 4.4 (95% CI 2.8–6.8).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMESA (4,955 subjects):\u003c\/strong\u003e Cardiovascular disease risk: HR 1.78 (95% CI 1.16–1.98).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMESA (6,814 subjects):\u003c\/strong\u003e With calcium score of 0: events in 1.3–5.6% of subjects. With calcium score \u0026gt;300: events in 13.1–25.6%.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eMeta-Analyses: Combining the Evidence\u003c\/h3\u003e\n\n\u003cp\u003eSeveral comprehensive meta-analyses have pooled data from multiple studies to compare imaging methods head-to-head. \u003cstrong\u003eDen Ruijter and colleagues\u003c\/strong\u003e (2012) analysed \u003cstrong\u003e14 population-based cohorts with data from 45,828 subjects\u003c\/strong\u003e, comparing common carotid IMT with the Framingham risk score. They found only a modest improvement in reclassification and hazard ratio, but \u003cstrong\u003eno significant improvement in AUC\u003c\/strong\u003e: Framingham AUC 0.76 (95% CI 0.75–0.76) vs. carotid IMT AUC 0.76 (95% CI 0.75–0.77).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eInaba and colleagues\u003c\/strong\u003e published a meta-analysis of \u003cstrong\u003e11 population-based studies including 54,336 patients\u003c\/strong\u003e. Compared with carotid IMT, \u003cstrong\u003ecarotid plaque was a significantly better predictor of future heart attack\u003c\/strong\u003e, with AUCs of 0.61 and 0.64, respectively (p = 0.04). The relative diagnostic odds ratio was 1.4 (95% CI 1.1–1.8; p = 0.04), meaning carotid plaque testing was 40% more accurate at distinguishing future heart attack victims from those who remained event-free.\u003c\/p\u003e\n\n\u003ch2 id=\"comparison\"\u003eCarotid Plaque vs. Coronary Calcium: Head-to-Head Comparisons\u003c\/h2\u003e\n\n\u003cp\u003eWhile earlier outcome studies compared one imaging method with traditional risk factors, two large-scale studies—\u003cstrong\u003eBioImage\u003c\/strong\u003e and \u003cstrong\u003eMESA\u003c\/strong\u003e—directly compared coronary calcium scoring with carotid ultrasound imaging in the same patients.\u003c\/p\u003e\n\n\u003cp\u003eThe \u003cstrong\u003eBioImage study\u003c\/strong\u003e, involving \u003cstrong\u003e5,808 healthy subjects\u003c\/strong\u003e and published in 2015 by Baber and colleagues, directly compared the total volume of carotid plaques (measured with the Philips iU 22 ultrasound system) with the presence and amount of coronary calcium. In a direct comparison, the predictive power for cardiovascular events was \u003cstrong\u003enon-inferior\u003c\/strong\u003e (equally good) in a low-to-intermediate-risk population. This is significant because coronary calcium scoring requires CT scanning (which involves radiation), while carotid ultrasound is radiation-free.\u003c\/p\u003e\n\n\u003cp\u003eThe \u003cstrong\u003eMESA study\u003c\/strong\u003e, which included \u003cstrong\u003e6,779 healthy subjects\u003c\/strong\u003e and was published by Gepner and colleagues in 2015, compared the presence of coronary calcium with carotid plaque and carotid IMT above the 75th percentile to predict cardiovascular events. The results were striking: \u003cstrong\u003eonly coronary calcium and carotid plaque presence were predictive—carotid IMT was not\u003c\/strong\u003e. For the prediction of stroke or transient ischemic attack, \u003cstrong\u003eonly the presence of carotid plaques was predictive\u003c\/strong\u003e after 9.5 years of observation time. This means that if you want to know your stroke risk, looking for carotid plaque is more informative than measuring IMT.\u003c\/p\u003e\n\n\u003ch2 id=\"treatment\"\u003eCan Medical Treatment Reverse or Slow Carotid Atherosclerosis?\u003c\/h2\u003e\n\n\u003cp\u003eIn a meta-analysis of \u003cstrong\u003e41 randomised trials including 18,307 participants\u003c\/strong\u003e published in 2010, active treatment (such as statins or blood pressure medications) \u003cstrong\u003esignificantly reduced cardiovascular events and all-cause death\u003c\/strong\u003e. However, there was \u003cstrong\u003eno significant relationship between IMT reduction and cardiovascular events\u003c\/strong\u003e—meaning that even when treatment didn't visibly shrink the artery lining, it still prevented heart attacks and strokes. This may seem counterintuitive, but it suggests that the benefits of treatment go beyond what ultrasound can measure in the artery wall.\u003c\/p\u003e\n\n\u003cp\u003eThis finding was later confirmed in a second meta-analysis by Goldberger and colleagues. However, it was \u003cstrong\u003enot confirmed in the IMPROVE-IT study\u003c\/strong\u003e, which included \u003cstrong\u003e3,703 high-risk patients\u003c\/strong\u003e (average Framingham risk score of 22%, meaning a 22% risk of a heart event within 10 years). In that study, carotid IMT and its progression—but not carotid plaque—led to significant improvements in risk reclassification. The differing results highlight that research is still evolving on which measurement best reflects treatment success.\u003c\/p\u003e\n\n\u003ch2 id=\"what-to-measure\"\u003eWhat Should Be Measured: IMT, Plaque, or Calcium?\u003c\/h2\u003e\n\n\u003cp\u003eCardiovascular risk increases with carotid plaque burden quantified as TPA. Spence performed a study with a \u003cstrong\u003e5-year observation time\u003c\/strong\u003e measuring the outcomes of heart attack, stroke, or vascular-related death and found that TPA strongly predicted these events.\u003c\/p\u003e\n\n\u003cp\u003eRegardless of traditional risk factors, structural arterial changes revealed by atherosclerosis imaging are associated with adverse cardiovascular outcomes. This is important because although screening with atherosclerosis imaging has \u003cstrong\u003enot yet received a Class I (highest-level) recommended indication in primary care\u003c\/strong\u003e, the reality is that \u003cstrong\u003emost cardiovascular events occur in people who are NOT at high cardiovascular risk as categorised by traditional risk factors\u003c\/strong\u003e. By inference, additional testing may be helpful in further cardiovascular risk stratification—especially for those in the \"intermediate risk\" grey zone.\u003c\/p\u003e\n\n\u003cp\u003eThe inclusion of carotid plaque quantification into cardiovascular risk prediction has significantly improved discrimination and reclassification of patients in primary care. Carotid plaque is caused by atherosclerosis, which involves the accumulation of foam cells, smooth muscle cells, calcifications, macrophages, lipid cores, and a fibrous cap within the artery wall.\u003c\/p\u003e\n\n\u003cp\u003eSeveral factors influence the choice of one test over another:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eExpertise and availability of the technology\u003c\/li\u003e\n  \u003cli\u003eCost of the procedure\u003c\/li\u003e\n  \u003cli\u003eRadiation burden (ultrasound has none; CT scans do)\u003c\/li\u003e\n  \u003cli\u003eValidity and reproducibility\u003c\/li\u003e\n  \u003cli\u003eFeasibility and how quickly the test can be performed\u003c\/li\u003e\n  \u003cli\u003eThe ability to track atherosclerosis over time to observe treatment effects\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn the authors' opinion, \u003cstrong\u003ecarotid TPA is probably the most suited measurement for clinical practice\u003c\/strong\u003e, followed by a search for femoral (leg) bifurcation plaque, aortic plaque, the use of the ankle-arm index, or measurement of plaque height with ultrasound in various vascular beds.\u003c\/p\u003e\n\n\u003cp\u003eMore sophisticated tests are often time-consuming and costly or involve radiation exposure, though it has recently been shown that radiation exposure from CT can be reduced. The acquisition of IMT is technically demanding: it requires an ECG signal to capture images during diastole (the resting phase of the heartbeat) and a room temperature of \u003cstrong\u003e22–25°C\u003c\/strong\u003e. Importantly, plaques should \u003cstrong\u003enot\u003c\/strong\u003e be excluded from measurements because including them improves predictive accuracy for cardiovascular events.\u003c\/p\u003e\n\n\u003cp\u003eA comparative study by Laclaustra and colleagues used coronary calcium (score \u0026gt;0 for presence and \u0026gt;300 for extent) as the \"gold standard\" and compared the ability of traditional risk factors, 3D carotid plaque volume, and 3D femoral plaque volume to correctly detect coronary calcium in the same subjects. According to this study, \u003cstrong\u003eboth carotid and femoral plaque were better markers for the presence and extent of coronary calcifications than traditional risk factors\u003c\/strong\u003e, and there was a tendency toward better performance of femoral over carotid plaque, especially in smokers. This suggests that checking the leg arteries may add value, particularly for people who smoke.\u003c\/p\u003e\n\n\u003cp\u003eThe authors also present the mathematical framework (Bayes' theorem) for combining imaging results with traditional risk assessment. The post-test probability calculations are:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003ePost-test probability (test positive) = (Prevalence × Sensitivity) \/ [(Prevalence × Sensitivity) + (1 – Prevalence) × (1 – Specificity)]\u003c\/li\u003e\n  \u003cli\u003ePost-test probability (test negative) = [Prevalence × (1 – Sensitivity)] \/ [(Prevalence × (1 – Sensitivity)) + (Specificity × (1 – Prevalence))]\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn plain language, this approach lets doctors update a patient's risk estimate based on whether the carotid ultrasound finds plaque. A positive scan in a patient with borderline risk can \"reclassify\" them into a higher-risk category that warrants more aggressive treatment.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eClinical Implications: What This Means for You\u003c\/h2\u003e\n\n\u003cp\u003eThe evidence strongly supports the value of carotid ultrasound for improving cardiovascular risk prediction. Key takeaways for patients include:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCarotid plaque presence matters more than IMT alone.\u003c\/strong\u003e Multiple large studies show that plaque is a more powerful predictor of heart attacks and strokes than the thickness of the artery lining.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCarotid ultrasound performs as well as coronary calcium scoring.\u003c\/strong\u003e The BioImage and MESA studies directly demonstrated that carotid plaque measurement is non-inferior to coronary calcium for predicting cardiovascular events—without the radiation exposure of CT scanning.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWomen may benefit greatly.\u003c\/strong\u003e In the Tromsø study, the risk of heart attack for women in the highest TPA third was 4.0 times that of the lowest third (95% CI 2.2–7.2), compared with 1.6 for men—a remarkable difference.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStroke risk is especially tied to carotid plaque.\u003c\/strong\u003e In the MESA study, only carotid plaque presence (not coronary calcium or IMT) predicted stroke\/TIA after 9.5 years.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTreatment can help even if IMT doesn't change.\u003c\/strong\u003e The meta-analyses showed that active treatment reduces events and death even when visible changes in IMT are absent—so don't be discouraged if a follow-up scan shows little change.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe European Joint ESC (European Society of Cardiology) guidelines now state that carotid artery scanning \u003cstrong\u003eshould be considered for adjusting the level of risk, especially in intermediate-risk subjects\u003c\/strong\u003e. This is an important shift toward personalised medicine—treating the actual disease rather than just the risk factor profile.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What the Research Cannot Tell Us\u003c\/h2\u003e\n\n\u003cp\u003eWhile the evidence is compelling, important limitations must be acknowledged:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo uniform definition of plaque.\u003c\/strong\u003e Different studies used different thresholds for defining plaque, making direct comparisons across studies difficult.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConflicting results on IMT.\u003c\/strong\u003e Some large studies (such as the Lorenz 2010 study and the Den Ruijter meta-analysis) found that IMT did not improve prediction beyond traditional risk models, although these studies often had low plaque prevalence or focused on the common carotid artery only.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIMT reduction ≠ event reduction.\u003c\/strong\u003e The 2010 meta-analysis of 41 trials showed no significant relationship between IMT reduction and cardiovascular events, suggesting IMT may not be a good surrogate marker for treatment success.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNot yet a Class I recommendation.\u003c\/strong\u003e Despite strong evidence, carotid ultrasound screening has not received the highest-level endorsement in primary care guidelines, in part due to concerns about cost-effectiveness and whether screening leads to better outcomes in unselected populations.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTechnical variability.\u003c\/strong\u003e IMT measurement requires strict protocols (ECG gating, temperature control, specific artery segments), which limits its reproducibility in routine clinical settings.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eObservational nature.\u003c\/strong\u003e Much of the outcome data comes from observational cohort studies, which can show associations but cannot prove that acting on the test results improves outcomes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLimited field of view.\u003c\/strong\u003e The 3D TPV technique covers only 3.8 cm of the carotid artery and may miss plaques located outside that range, though TPA captures a longer segment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"\n\n\u0026lt;!-- ddn:faq:start --\u0026gt;\n\u0026lt;h2 id=\" ddn-faq\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is carotid ultrasound and what does it measure?\u003c\/h3\u003e\n\u003cp\u003eCarotid ultrasound is a safe, painless imaging test that uses a handheld probe on the neck to measure fatty plaque buildup in the neck arteries. It shows the actual disease, not just risk factors. Directly seeing plaque helps doctors predict heart attacks and strokes more accurately than traditional risk calculators alone.\u003c\/p\u003e\n\u003ch3\u003eWhy might I need carotid ultrasound if my cholesterol and blood pressure are normal?\u003c\/h3\u003e\n\u003cp\u003eMany people who have a first heart attack or stroke were previously labeled 'low risk' by standard calculators like PROCAM and SCORE. Carotid ultrasound can find plaque that those calculators miss. Measuring plaque, rather than only risk factors, may reclassify you into a more accurate risk category and lead to better prevention.\u003c\/p\u003e\n\u003ch3\u003eHow does carotid ultrasound compare with coronary calcium scoring?\u003c\/h3\u003e\n\u003cp\u003eIn head-to-head studies like BioImage and MESA, carotid plaque measurement was equally good at predicting cardiovascular events as coronary calcium scoring—but without radiation. For stroke risk specifically, only carotid plaque presence, not coronary calcium or IMT, was predictive after 9.5 years in the MESA study.\u003c\/p\u003e\n\u003ch3\u003eWhat is the difference between carotid IMT and carotid plaque?\u003c\/h3\u003e\n\u003cp\u003eIMT is the thickness of the artery's inner two layers, while plaque is a focal thickening or buildup of fatty material. Many large studies show plaque is a stronger predictor of heart attacks and strokes than IMT alone. Including plaque in measurements improves predictive accuracy compared to measuring just IMT.\u003c\/p\u003e\n\u003ch3\u003eCan carotid ultrasound predict my risk of stroke specifically?\u003c\/h3\u003e\n\u003cp\u003eYes. In the MESA study, only the presence of carotid plaque predicted future stroke or transient ischemic attack—not coronary calcium or IMT. Other studies, such as the Japanese 1995 study and the Tromsø study, also found that carotid plaque and stenosis predicted ischemic stroke. Measuring plaque helps assess stroke risk.\u003c\/p\u003e\n\u003ch3\u003eWill treatment help even if my follow-up ultrasound shows no change in IMT?\u003c\/h3\u003e\n\u003cp\u003eYes. A meta-analysis of 41 randomized trials with 18,307 participants found that active treatment significantly reduced cardiovascular events and death, even when there was no visible reduction in IMT. So don't be discouraged if a follow-up scan shows little change; treatment still prevents heart attacks and strokes.\u003c\/p\u003e\n\u003ch3\u003eWhat are the limitations of carotid ultrasound for risk prediction?\u003c\/h3\u003e\n\u003cp\u003eThere is no uniform definition of plaque, and studies used different thresholds. Some large studies found IMT did not improve prediction, and IMT reduction does not equal fewer events. Carotid ultrasound is not yet a Class I recommended screening test for everyone. Technical variability and limited field of view also matter.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47415300063388,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/products\/seeing-the-problem-before-it-happens-how-carotid-ultrasound-helps-predict-heart-attacks-and-strokes","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}